Single-nucleotide polymorphisms in the p53 signaling pathway. by Grochola, L, Zeron-Medina, J, Mériaux, S, Bond, G

MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation. by Grochola, L, Müller, T, Bond, G, Taubert, H, Udelnow, A, Würl, P

Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival. by Grochola, L, Vazquez, A, Bond, E, Würl, P, Taubert, H, Müller, T, Levine, A, Bond, G

Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. by Vazquez, A, Grochola, L, Bond, E, Levine, A, Taubert, H, Müller, T, Würl, P, Bond, G

A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence. by Vazquez, A, Kulkarni, D, Grochola, L, Bond, G, Barnard, N, Toppmeyer, D, Levine, A, Hirshfield, K

A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. by Yee, K, Grochola, L, Hamilton, G, Grawenda, A, Bond, E, Taubert, H, Wurl, P, Bond, G, O'Neill, E

CD44 SNP rs187115: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma. by Stracquadanio, G, Vrugt, B, Flury, R, Schraml, P, Würl, P, Müller, T, Knippschild, U, Henne-Bruns, D, Breitenstein, S, Clavien, P, Graf, R, Bond, G, Grochola, L

Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. by Lenos, K, Grawenda, A, Lodder, K, Kuijjer, M, Teunisse, A, Repapi, E, Grochola, L, Bartel, F, Hogendoorn, P, Wuerl, P, Taubert, H, Cleton-Jansen, A, Bond, G, Jochemsen, A